- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06277986
Early Diagnosis of Gastric Cancer Cachexia
February 18, 2024 updated by: Xijing Hospital
Clinical Value of Tumor Cell-derived Exosomal miRNA in Early Diagnosis of Gastric Cancer Cachexia
Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest.
In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia.
However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment.
Therefore, it is important to find biomarkers for early detection of cachexia.
The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.
Study Overview
Detailed Description
Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest.
In gastric cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia.
However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment.
Therefore, it is important to find biomarkers for early detection of cachexia.
The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.
Study Type
Observational
Enrollment (Estimated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jipeng Li
- Phone Number: +86-029-84771533
- Email: jiangxunliang1992@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Recruiting
- Fourth Military Medical University
-
Contact:
- Jipeng Li
- Phone Number: +86-029-84771533
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The research object is patients with confirmed gastric cancer.According to diagnostic criteria, patients are divided into cachexia group and non-cachexia group.
Description
Inclusion Criteria:
- Patients with gastric cancer diagnosed by histopathology or cytopathology
- Complete clinical and pathological data
- No previous or current mental illness or disturbance of consciousness
Exclusion Criteria:
- With multiple tumors or other malignant diseases
- Combined with other chronic wasting and metabolic diseases
- Past patients with non-tumor cachexia
- People with mental illness or unable to cooperate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Gastric cancer patients with non-cachexia
|
Cachexia mainly manifests as weight loss.
1)weight loss >5% over past 6 months.
2)BMI<20 and any degree of weight loss >2%.
3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss >2%.
|
Gastric cancer patients with cachexia
|
Cachexia mainly manifests as weight loss.
1)weight loss >5% over past 6 months.
2)BMI<20 and any degree of weight loss >2%.
3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss >2%.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI
Time Frame: six months
|
Calculate BMI based on changes in body weight in the past six months
|
six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2021
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
January 16, 2022
First Submitted That Met QC Criteria
February 18, 2024
First Posted (Estimated)
February 26, 2024
Study Record Updates
Last Update Posted (Estimated)
February 26, 2024
Last Update Submitted That Met QC Criteria
February 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY20212018-F-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cachexia
-
Wageningen UniversityTop Institute Food and Nutrition; Gelderse Vallei HospitalRecruiting
-
Oncocross Australia Pty Ltd.CompletedCancer CachexiaAustralia
-
Hospital Erasto GaertnerCompletedCachexia; CancerBrazil
-
Garcia, Jose M., MD, PhDBaylor College of Medicine; VA Office of Research and Development; AEterna ZentarisCompletedCancer CachexiaUnited States
-
Zhejiang Kanglaite Pharmaceutical Co.LtdLinkDoc Technology (Beijing) Co. Ltd.; NanJing PLA 81 HospitalUnknown
-
Zhejiang Kanglaite Pharmaceutical Co.LtdH & J CRO International, Inc.Unknown
-
Helsinn Therapeutics (U.S.), IncCompletedCancer CachexiaUnited States
-
Helsinn Therapeutics (U.S.), IncCompletedCancer CachexiaUnited States
-
University of Roma La SapienzaCompleted
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingCancer Cachexia (CC)United States
Clinical Trials on cachexia
-
University of CopenhagenCompletedQuality of Life | Cancer Cachexia | Side EffectsDenmark
-
German Cancer Research CenterHeidelberg University; Technical University of MunichWithdrawn
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Neutropenia | InfectionUnited States
-
Cyprus University of TechnologyGerman Oncology Center, CyprusRecruitingNeoplasms | Cancer | Malnutrition | Cachexia | Educational ProblemsCyprus
-
Puneeth IyengarIncyte CorporationRecruiting
-
Smartfish ASCompletedCachexia | COPDSweden
-
Smartfish ASCompletedNSCLC | CachexiaItaly, Sweden, Croatia, Slovakia
-
University of CopenhagenRigshospitalet, DenmarkCompletedAbdominal Cancer | ComplianceDenmark
-
University of FloridaCompletedMalignant Neoplasm of Gastrointestinal TractUnited States
-
ADDMEDICA SASACompletedSickle Cell DiseaseFrance